

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: EXMceuticals Inc. (the "Issuer").

Trading Symbol: EXM

Number of Outstanding Listed Securities: 75,167,510

Date: August 31, 2020

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

All of EXM's active business operations are in near Lisbon, Portugal, in Europe. In late 2019 the Issuer obtained the official full license for cannabis research and development from the Portuguese National Authority of Medicines and Health Products (INFARMED). This license now allows the Issuer to research and refine cannabinoids and cannabis by-products inside Portugal / Europe, as well as to operate the existing R&D facility. Operations at the licensed facility were suspended on March 12th due to the emerging health regulations imposed by the Portuguese government as part of the measures taken to limit the effects of COVID 19.

Operations at the R&D facility are now active having had all the Covid staff security measures installed and in practise. Steps are being taken to procure meaningful amounts of cannabis raw materials from third party suppliers to immediately restart

at scale an enhanced programme of cannabinoid research, and product formulation. Portuguese management is finalizing active discussions with third party potential sources and growers of cannabis, hemp biomass and extract, within Portugal and also outside Europe, that will be used to fill resource requirements for the industrial facility.

Management is actively seeking offtake agreements from pharmaceutical and wellness buyers for the future planned commercial production of cannabinoids.

2. Provide a general overview and discussion of the activities of management.
In August 2020, management focussed on the finalisation of the conversion of various outstanding loan agreements into common shares of the company, including the issuance of the relevant bonus securities. EXMceuticals was also able to settle substantial outstanding unpaid working capital liabilities through the issuance of 4,139,161 shares. On the 28th of the month 518,451 previously issued shares were returned to the company treasury and will be cancelled. These measures, combined with the share issuance and loan conversions that occurred in July, have very substantially reduced the company's unpaid invoice, account payable and debt obligations. Exmceuticals Portugal : Management have been pushing forward with the acceleration of the companies R&D program into cannabinoids and Terpenes, with a particular focus on how the relevant molecules could assist in the fight against Covid 19. Management has also arranged for a bulk shipment (combined in excess of 17kg) of high quality cannabinoid distillate into Portugal and this is expected in the early days of September. All the required regulatory approvals have been achieved. Relevant cannabinoid material being imported includes terpenes, cbd, cbn and CBG. These materials will enable a full programme of research to be commenced and completed in coming months, as well as enable the supply of pure samples of the relevant cannabinoids to scientific and R&D partners. These materials will also enable the completion of the protocol and equipment calibration work for the planned industrial refinery.

3. or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Not applicable

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
Not applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
Management continues to negotiate with third party potential sources and growers of cannabis and hemp biomass and extract, within Portugal and also outside Europe, that will be used to fill resource requirements for the industrial facility. Management has a number of MOU's under discussion in this area.

Management continues to negotiate with offtakers and potential buyers of refined and finished cannabinoids inside Portugal, Europe and beyond. These relationships and eventual offtake's will be used to allocate the planned initial production of the refinery.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable

8. Describe the acquisition of new customers or loss of customers.

Not applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

On the 28th of the month 518,451 previously issued shares were returned to the company treasury and will be cancelled. These measures, combined with the share issuance and loan conversions that occurred in July, have very substantially reduced the companies unpaid invoice, account payable and debt obligations.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Date Issued	Details of Issuance	Use of Proceeds (1)
Common Shares	2,278,353	08/06/2020	Loan	N/A
Common Shares	4,139,161	08/20/2020	Debt settlement agreements	N/A
Common Shares	518,451	08/28/2020	cancellation of escrow shares	N/A

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

The outstanding principal amount of loans owed by the Issuer to certain lenders is \$500,000.

16. Provide details of any changes in directors, officers or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Other trends and risks which are likely to impact the Issuer are discussed in the Issuer's Form 2A Listing Statement dated January 28, 2019 and filed on the CSE website and SEDAR. The Issuer's audited annual financial statements (the "Annual Financials") and corresponding management's discussion and analysis (the "Annual MD&A") for the year ended June 30, 2019 also discuss risks which are likely to impact the Issuer. The Annual Financials and Annual MD&A are both available under the Issuer's profile on SEDAR at www.sedar.com.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: Sept 4, 2020

Julie Lemieux _____
Name of Director or Senior Officer

/s/ "Julie Lemieux" _____
Signature

Corporate Secretary _____
Official Capacity

Issuer Details Name of Issuer EXMceuticals Inc.	For Month End August 2020	Date of Report YY/MM/DD 20/09/03
Issuer Address 421 7th Avenue S.W. 30th Floor		
City/Province/Postal Code Calgary, AB, T2P 4K9	Issuer Fax No.	Issuer Telephone No. 587.390.8541
Contact Name Julie Lemieux	Contact Position Corporate Secretary	Contact Telephone No. 587.390.8541
Contact Email Address julie@exmceuticals.com	Web Site Address www.exmceuticals.com	